Modera Wealth Management LLC Takes Position in Moderna, Inc. (NASDAQ:MRNA)

Modera Wealth Management LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 5,562 shares of the company’s stock, valued at approximately $231,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB grew its holdings in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after buying an additional 664 shares during the last quarter. Compass Planning Associates Inc acquired a new position in Moderna during the 4th quarter worth about $37,000. Larson Financial Group LLC grew its holdings in Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after acquiring an additional 317 shares during the last quarter. Finally, Rakuten Securities Inc. increased its position in Moderna by 477.3% in the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after acquiring an additional 778 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of research reports. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Bank of America reduced their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a report on Tuesday, February 11th. Evercore ISI set a $50.00 target price on Moderna in a research note on Friday, February 14th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Finally, JPMorgan Chase & Co. set a $45.00 price target on Moderna in a report on Friday, February 14th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $60.63.

Moderna Stock Up 15.9 %

Shares of MRNA stock opened at $35.21 on Thursday. The firm has a market capitalization of $13.58 billion, a price-to-earnings ratio of -3.79 and a beta of 1.86. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The firm has a fifty day moving average of $36.82 and a 200-day moving average of $49.78.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.